Glaucoma eye drops in drugstores in key cities increased rapidly with an increase rate of 35%

March 6 is World Glaucoma Day At present, there are about 67 million glaucoma patients in the world It is estimated that there will be 79.6 million glaucoma patients by 2020, with a blindness rate of 14% Glaucoma has certain heredity, and it is possible for people of all ages to get sick It has become the killer of blindness The purpose of strengthening the understanding of glaucoma is to further popularize the scientific knowledge of eye protection and embrace the bright and colorful world   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box side: border box! Im portant; word wrap: break word! Im portant; "> the state attaches great importance to the diagnosis and treatment of glaucoma in May 2014 The ophthalmology branch of the Chinese Medical Association issued the consensus on the examination, diagnosis and treatment of primary glaucoma in China (2014), which plays an important guiding role in improving the diagnosis and treatment of glaucoma In 2017, the ophthalmic drugs included in the chemical medicine section of the newly issued national medical insurance drug catalog were divided into nine categories, with a total of 64 drugs In each small class, the number of anti glaucoma agents is the first, containing 12 drugs They are pilocarpine, timolol, acetazolamide, bemeprost, betalol, brinzolam, acetazolamide, captalol, latanoprost, travoprost, bromonidine and levobunolol Among them, acetazolamide is a new drug added in 2017 As we all know, glaucoma is a kind of ophthalmopathy with high intraocular pressure, which affects the normal function of optic nerve papilla It is one of the main ophthalmopathy causing blindness The disease has been paid attention by the domestic and foreign governments In order to further standardize the diagnosis and treatment of glaucoma, the clinical use of glaucoma in China has been basically synchronized with that in the United States, Europe and the Asia Pacific region none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0,0); box sizing: border box! Im assistant; word wrap: break word! Im assistant; "> the annual sales of the two products are more than 100 million With China's full access to the aging society, all kinds of eye diseases are increasingly prominent According to epidemiological research, glaucoma is the second leading cause of blindness after cataract According to the shape of the onset and anterior chamber angle, it can be divided into acute, chronic angle closure glaucoma and open angle glaucoma Different types of glaucoma have different clinical manifestations, characteristics and treatment methods At present, anti glaucoma drugs, laser and surgical treatment are the three major means in clinical, and according to the type and progression of glaucoma, drug treatment is still the first choice According to minenet data, in 2016, the sales volume of ophthalmic drugs in pharmacies in key cities reached 1.517 billion yuan, an increase of 17.35% compared with the previous year, and 11.54% higher than that of public hospitals in key cities With the trend of hospital prescription outflow, hospital drug control measures and the improvement of social consumption level advocated by the state, the retail ophthalmic drug market of urban pharmacies shows a rapid growth trend There are about 20 varieties of glaucoma retail drugs in drugstores in key cities in China, with a retail amount of 39.44 million yuan, up 35% year on year The top 10 eye drops were brinzolam, cattellol, travoprost, bromonidine, latanoprost, timolol, betamethasone timolol, betalol, clonidine and pilocarpine none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0,0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> brinzolam leads the glaucoma drugstore market, with an increase of 51.62% and belongs to carbonic anhydrase inhibitor It was first listed in the United States in April 1998 and has been listed in nearly 30 countries in the world In 2002, China approved the import of elkang's brinzolamide, which is named azopt, and belongs to class B medical insurance Brinzolam eye drops are the first choice for glaucoma patients who are contraindicated to β - blockers and can not tolerate mydriasis This kind of drugs is mainly to directly inhibit the activity of carbonic anhydrase in ciliary epithelium, thus reducing the generation of aqueous humor, reducing intraocular pressure, with the characteristics of good selectivity and high affinity, so it is favored by doctors and patients As the first eye drops of carbonic anhydrase inhibitor in China, the sales of brinzolam in the hospital rose all the way after its listing, and the retail market also has good performance According to the data of minenet, in 2016, the retail sales of brinzolam eye drops in key city drugstores in China reached 11.94 million yuan, an increase of 51.62% over the previous year, which was exclusively sold by elkon's paramount   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the growth rate of catolol eye drops is nearly 60%, which is developed by Otsuka company of Japan It was approved by FDA in May 1990 and listed under the name of Meikai As a non selective β - receptor blocker, Michelson can block both β 1 and β 2-receptors, which can reduce intraocular pressure by 22% - 25% It has a good effect on reducing intraocular pressure in primary open-angle glaucoma The main metabolite of this product, 8-hydroxy-catalol, also has the effect of reducing intraocular pressure In the mid-1990s, CFDA approved the cataprolol eye drops of Otsuka Pharmaceutical (Tianjin) in China, and the new xidin of hanlim pharmaceutical in South Korea in 2014 According to the data of mienei.com, in 2016, the retail sales of drug stores in key cities in China reached 10.87 million yuan, with a year-on-year growth rate of 58.81% China Otsuka Pharmaceutical (Tianjin) Co., Ltd owns 100% of the market none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Su Weitan, the leader of prostaglandin eye drops, has clearly proposed that prostaglandin derivatives can be used as the first-line drugs for primary open-angle glaucoma in the consensus on the examination, diagnosis and treatment of primary glaucoma (2014), and proposed that prostaglandin drugs are the most effective specialized drugs for reducing intraocular pressure Travoprost eye drops, a new product developed by Alcon universal in the UK, was officially approved by the FDA in September 2006 and then listed in China under the trade name of Travatan Travoprost is the precursor of isopropyl ester It is hydrolyzed to free acid with biological activity by corneal absorption In the whole body metabolism, travoprost free acid can be oxidized to non active metabolites Fully activate the FP receptor, so as to cause the outflow of aqueous humor, provide a strong role in reducing intraocular pressure, protect the patient 's visual field, and reduce the elevated intraocular pressure in patients with open-angle glaucoma or high intraocular pressure According to the data of mienei.com, in 2016, the retail sales of travoprost in key cities in China reached 5.61 million yuan, an increase rate of 2.32% over the previous year, and the market was monopolized by Travatan of Erkang company In addition, Erkang's compound travoxil (travoprost + timolol maleate) eye drops have also been listed in China, and its trade name is duotrav, which is in its infancy   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> latanoprost and latanolatanoprost are the first anti glaucoma prostaglandin drugs approved by FDA Now they are products of Pfizer, and the trade name is Xalatan Latanoprost, a prostaglandin F2 α analogue, is a selective prostaglandin receptor agonist It can reduce intraocular pressure by increasing the outflow of the uveoscleral accessory pathway of aqueous humor The dosage of latanoprost is small, and it has a good effect of reducing intraocular pressure It is mainly used in open-angle glaucoma and ocular hypertension China began to import this product in 1999, which is the first-line drug for clinical treatment of glaucoma in domestic hospitals The imported latanoprost eye drops used in clinic are Xalatan of Pfizer and ridaxi of taejoon Pharm of South Korea The latanoprost eye drops produced by 5 domestic manufacturers have been approved for listing According to the data of mienei.com, the sales volume of latanoprost, a drugstore in key cities in China, was 2.46 million yuan in 2016, with a year-on-year growth rate of 46.27% In 2016, among the latanoprost competitors of drugstores in key cities in China, Pfizer's gelida accounted for 86.80% of the retail share, China Resources Zizhu's Jiankang accounted for 9.64%, lunanbeite's Telijie accounted for 2.75%, South Korea's taekoon Pharm's ruidaxi accounted for 0.72%, and Chengdu Hengrui's san'ao accounted for 0.09% The highest growth rate was found in Jiankang, with 617.13% In October 2001, FDA approved the listing of compound latanoprost / timolol eye drops of Pfizer, which was used to reduce the elevated intraocular pressure of patients with open-angle glaucoma and high intraocular pressure, and applied to the symptoms with poor local treatment effect of β - blocker It entered the Chinese market in 2008, and the trade name was siligar On November 21, 2017, CFDA approved the launch of latantetamethine, the first generic drug for glaucoma, which was developed by Qilu pharmaceutical It broke the foreign monopoly and made a new first-line drug choice for tens of millions of patients suffering from glaucoma none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box sizing: border box! Im assistant; word wrap: break word! Im assistant; "> bromonine